Recombinant soluble thrombomodulin as an adjunctive treatment for sepsis and disseminated intravascular coagulation: Relatively safe and possibly effective

Critical Care Medicine

Volumn 41, Issue 9, 2013, Pages 2221-2223

  Fink, Mitchell P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

activated protein C; clinical trial; coagulation; endothelial cells; sepsis

Indexed keywords

ACTIVATED PROTEIN C; ADVANCED GLYCATION END PRODUCT; AMINO ACID; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; CHONDROITIN SULFATE; DROTRECOGIN; ENZYME PRECURSOR; GLYCOSAMINOGLYCAN; INTERLEUKIN 6; INTERLEUKIN 8; LECTIN; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT THROMBOMODULIN; THROMBIN; THROMBOCYTE FACTOR 4;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; CELL MEMBRANE; CELL TYPE; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTERNATIONAL NORMALIZED RATIO; LIPOPHILICITY; LYMPH VESSEL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; TISSUE INJURY;

DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; MALE; RECOMBINANT PROTEINS; SEPSIS; THROMBOMODULIN;

EID: 84883637287     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182964037     Document Type: Review

References (19)

1. Owen WG, Esmon CT: Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1981; 256:5532-5535
2. Conway EM: Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34:107-125
3. Lin SM, Wang YM, Lin HC, et al: Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med 2008; 36:683-689
4. Coughlin SR, Camerer E: PARticipation in inflammation. J Clin Invest 2003; 111:25-27
5. Fink MP: Bench-to-bedside review: High-mobility group box 1 and critical illness. Crit Care 2007; 11:229
6. Abeyama K, Stern DM, Ito Y, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115:1267-1274
7. Ito T, Kawahara K, Okamoto K, et al: Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008; 28:1825-1830
8. Uchiba M, Okajima K, Murakami K, et al: Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 1996; 271(3, Part 1):L470-L475
9. Hagiwara S, Iwasaka H, Matsumoto S, et al: In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 2010; 33:282-288
10. Nagato M, Okamoto K, Abe Y, et al: Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009; 37:2181-2186
11. Saito H, Maruyama I, Shimazaki S, et al: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, doubleblind clinical trial. J Thromb Haemost 2007; 5:31-41
12. Yamakawa K, Fujimi S, Mohri T, et al: Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: A historical control study. Crit Care 2011; 15:R123
13. Kato T, Sakai T, Kato M, et al: Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: A retrospective cohort study. Thromb J 2013; 11:3
14. Ogawa Y, Yamakawa K, Ogura H, et al: Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012; 72:1150-1157
15. Vincent J-L, Ramesh MK, Ernest D, et al: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation. Crit Care Med 2013; 41:2069-2079
16. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
17. Opal SM, Laterre PF, Francois B, et al; ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 2013; 309:1154-1162
18. Guntupalli K, Dean N, Morris PE, et al; TLF LF-0801 Investigator Group: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med 2013; 41:706-716
19. Wunderink RG, Laterre PF, Francois B, et al; CAPTIVATE Trial Group: Recombinant tissue factor pathway inhibitor in severe communityacquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2011; 183:1561-1568